E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to assess the long-term safety and efficacy of eculizumab in
hemolytic PNH patients who completed the 4-week screening and 12-week treatment period of the
C07-001 study. In addition, pharmacokinetic and pharmacodynamic assessments of eculizumab
were conducted.